Please login to the form below

Not currently logged in
Email:
Password:

parkinson's disease

This page shows the latest parkinson's disease news and features for those working in and with pharma, biotech and healthcare.

Eli Lilly shutters UK neuroscience unit, with 80 job losses expected

Eli Lilly shutters UK neuroscience unit, with 80 job losses expected

Its pipeline currently includes solanezumab for Alzheimer’s – which has already failed earlier phase 3 trials – along with two antibodies for the disease in mid-stage testing (donanemab and zagotenemab) and ... a small-molecule dopamine D1

Latest news

  • Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder

    The move for Alder comes as Lundbeck – a specialist in central nervous system disease therapies – is trying to bulk up its product pipeline to help it cope with patent expiries for ... $1b purchase of  Prexton Therapeutics and phase 2 Parkinson’s

  • Bayer takes control of BlueRock stem cell joint venture Bayer takes control of BlueRock stem cell joint venture

    The decision gives Bayer complete control of BlueRock’s cell therapy pipeline headed by a candidate for Parkinson’s disease that is due to start clinical trials this year and spanning ... The deal values BlueRock at around $1bn. The lead programme in

  • CHMP backs Bayer’s tumour-agnostic drug Vitrakvi CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

    The ‘histology-independent’ treatment should be used for patients whose disease has spread or cannot be surgically removed, and who have no other satisfactory treatment options, says the CHMP.  NTRK fusions ... periods in Parkinson’s disease, as

  • Acadia’s drive to extend use of Nuplazid hits a wall Acadia’s drive to extend use of Nuplazid hits a wall

    Shares in company down. Acadia Pharmaceutical’s Nuplazid was the first-ever drug to be approved to treat psychosis associated with Parkinson’s disease, but the company’s hopes of extending ... Nuplazid (pimavanserin) is Acadia’s only approved

  • Intec sounds a sad note as Accordion Parkinson’s trial fails Intec sounds a sad note as Accordion Parkinsons trial fails

    Intec’s lifeline now is Novartis partnership. Shares in Intec Pharma have been poleaxed after a phase 3 trial of a Parkinson’s disease drug based on its Accordion delivery technology ... to the patient, performed no better than the standard

More from news
Approximately 25 fully matching, plus 191 partially matching documents found.

Latest Intelligence

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    Two further candidates, AL003 for Alzheimer’s disease and AL004 for multiple degenerative disorders, are also set to enter clinical trials this year. ... Diseases include Alzheimer’s, dementia with Lewy bodies, frontotemporal dementia, as well as

  • Key considerations for disease- modifying Parkinson’s disease trials Key considerations for disease- modifying Parkinsons disease trials

    Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s.The anti-Parkinson medications available primarily promote dopamine levels in the brain to compensate for the loss of ... Make sure the study population is

  • A quest for innovative solutions A quest for innovative solutions

    It is this quest for technology that can help patients with epilepsy and Parkinson’s, the sweet spots in its global operation that saw total revenue grow to 4.2bn in ... We have huge support to translate that change for both others in the organisation

  • Pfizer and IBM's tech-enabled 'Parkinson’s house' Pfizer and IBM's tech-enabled 'Parkinsons house'

    But this elegant home, surrounded by manicured lawns, is wired to beat the scourge of Parkinson’s disease. ... first patient for a Parkinson’s disease clinical trial.

  • Pharma deals continue to slide Pharma deals continue to slide

    an antibody for treatment of Parkinson’s disease. ... MEDI1341, an alpha-synuclein antibody entering phase I for treatment of Parkinson’s disease.

More from intelligence
Approximately 0 fully matching, plus 25 partially matching documents found.

Latest appointments

  • Prevail Therapeutics adds to its board of directors Prevail Therapeutics adds to its board of directors

    The Prevail team has already made great progress in developing potential treatments for Parkinson’s disease and other neurodegenerative diseases, and I look forward to partnering with the team to help

  • Voyager Therapeutics appoints Matthew Ottmer as chief operating officer Voyager Therapeutics appoints Matthew Ottmer as chief operating officer

    He said: “I am thrilled to join Voyager at this important time during the company’s evolution. ... Developing and implementing the initial commercial strategy and planning for VY-AADC for Parkinson’s disease is a top priority, especially as we

  • Newron Pharma appoints commercial affairs VP Newron Pharma appoints commercial affairs VP

    He brings sales and marketing experience from Johnson &Johnson, and served as franchise marketing director for psychiatry, Parkinson's disease and migraine products at Novartis. ... future. “At the same time we welcome Dennis as a new member of

  • Voyager Therapeutics appoints chief financial officer Voyager Therapeutics appoints chief financial officer

    This strong foundation combined with the company's recent positive interim phase Ib data from its lead program VY-AADC01 for advanced Parkinson's disease and the opportunity to join a ... I am thrilled to join the Voyager team and meaningfully contribute

  • Pfizer appoints chief scientific officer Pfizer appoints chief scientific officer

    Having first joined Harvard in 1989, Dr Isacson's work in neurogenerative disorders, particularly for Parkinson's disease, has become internationally renowned with his laboratory now one of the leading academic ... s disease, where we are working to

More from appointments
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest from PMHub

  • The dark side of direct-to-consumer genetic tests

    Instead,   they interpret single-nucleotide polymorphisms (SNPs), and while SNPs can indicate a gene is associated with a disease, many are benign and have no impact on health. ... Who can blame them? If an email landed in your inbox that appeared to

  • The power of the patient

    In this episode, we talk to Matt Eagles who was diagnosed with Parkinson's Disease aged just eight. ... He has also written a series of articles for Parkinson's UK in their Quarterly Journal.

  • Leading Edge expands their senior medical writing team

    of Oxford, where she studied the use of stem cells as an in-vitro model of Parkinson’s disease.

  • Top 7 Trends in Pharma Marketing for 2015

    Wearable tech will play an even more integral role in the collection of aggregated patient data to help identify disease trends, predict treatment outcomes and improve future diagnoses. What we anticipate ... are collaborating with 23andMe to analyse

  • How can pharma help doctors in treating neurological disorders?

    The large number of treatments that are now available to treat neurological disorders, such as multiple sclerosis (MS) and Parkinson’s disease, and the complex nature of these medications, are key

More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics